Abbott Laboratories shares surged 12% after the healthcare company reported strong second-quarter sales, raised its full-year earnings outlook and reaffirmed revenue growth guidance. Progress across its medical devices and diagnostics pipeline further boosted investor confidence in future growth.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.